Pregled bibliografske jedinice broj: 1145779
Effects of carvedilol therapy in patients with heart failure with preserved ejection fraction – Results from the Croatian heart failure (CRO-HF) registry
Effects of carvedilol therapy in patients with heart failure with preserved ejection fraction – Results from the Croatian heart failure (CRO-HF) registry // Medicina clinica, 152 (2019), 2; 43-49 doi:10.1016/j.medcli.2018.02.011 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1145779 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Effects of carvedilol therapy in patients with
heart failure with preserved ejection fraction –
Results from the Croatian heart failure (CRO-HF)
registry
Autori
Marković, Domagoj ; Jurčevic Zidar, Branka ; Macanović, Jelena ; Miličić, Davor ; Glavaš, Duška
Izvornik
Medicina clinica (0025-7753) 152
(2019), 2;
43-49
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
carvedilol ; diastolic dysfunction ; disfunción diastólica ; fracción de eyección preservada ; heart failure ; insuficiencia cardíaca ; Mortalidad ; Mortality ; Preserved ejection fraction
Sažetak
Background and objective: According to recent guidelines, the best approach for treatment of heart failure patients with preserved ejection function is still not defined. The aim of this study was to investigate how carvedilol therapy influences the survival rate, ejection fraction and NYHA class in these patients. Patients and methods: We conducted study on heart failure patients with preserved systolic function from the Croatian heart failure registry who were hospitalized in the period between 2005 and 2010. We enrolled patients with carvedilol listed as treatment on their discharge letters and patients who had been using carvedilol for at least 4 years, while for the control group we selected patients with no beta-blockers on their discharge letters (113 vs 204 respectively). The primary outcome was the overall survival rate and the secondary outcome was the change in ejection fraction of the left ventricle and NYHA class during the study. Results: Patients in the carvedilol group had a higher overall survival rate compared to patients in the control group (chi-square=14.1, P<0.001). Patients in the carvedilol group in two measurements had a significantly higher ejection fraction compared to the control group (F=148.04, P<0.001). Also, patients in the carvedilol group showed improvement in NYHA class (chi- square=29.768, P<0.001). Conclusion: Long term carvedilol therapy appears to be associated with a higher overall survival rate, improvement in ejection fraction and NYHA class in heart failure patients with preserved ejection fraction.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
KBC Split,
Medicinski fakultet, Split
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE